Christina M. Annunziata

Publications

• Loss of Compensatory Pro-survival and Anti-apoptotic Modulator, IKKε, Sensitizes Ovarian Cancer Cells to CHEK1 Loss Through an Increased Level of P21
  Oncotarget. Dec, 2014  |   Pubmed ID: 25474241
• The Small Molecule NSC676914A is Cytotoxic and Differentially Affects NFκB Signaling in Ovarian Cancer Cells and HEK293 Cells
  Cancer Cell International. 2014  |   Pubmed ID: 25324692
• Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-associated Breast or Ovarian Cancer with Biomarker Analyses
  Journal of the National Cancer Institute. Jun, 2014  |   Pubmed ID: 24842883
• Pathway-specific Engineered Mouse Allograft Models Functionally Recapitulate Human Serous Epithelial Ovarian Cancer
  PloS One. 2014  |   Pubmed ID: 24748377
• A Phase II Clinical Trial of Polyethylene Glycol-conjugated L-asparaginase in Patients with Advanced Ovarian Cancer: Early Closure for Safety
  Molecular and Clinical Oncology. May, 2013  |   Pubmed ID: 24649212
• Novel Facts About FAK: New Connections to Drug Resistance?
  Journal of the National Cancer Institute. Oct, 2013  |   Pubmed ID: 24062526
• Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort
  Molecular & Cellular Proteomics : MCP. Jun, 2013  |   Pubmed ID: 23449826
• Evolutionarily Conserved Protein ERH Controls CENP-E MRNA Splicing and is Required for the Survival of KRAS Mutant Cancer Cells
  Proceedings of the National Academy of Sciences of the United States of America. Dec, 2012  |   Pubmed ID: 23236152
• IKK-ε Coordinates Invasion and Metastasis of Ovarian Cancer
  Cancer Research. Nov, 2012  |   Pubmed ID: 22942254
• Phase 1, Open-label Study of MEDI-547 in Patients with Relapsed or Refractory Solid Tumors
  Investigational New Drugs. Feb, 2012  |   Pubmed ID: 22370972
• Targeting the Proteasome with Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit As an Upfront Single Agent, Induction Regimen for Stem-cell Transplantation and As Maintenance Therapy
  American Journal of Therapeutics. Mar, 2012  |   Pubmed ID: 21248621
• A Mechanistic Rationale for MEK Inhibitor Therapy in Myeloma Based on Blockade of MAF Oncogene Expression
  Blood. Feb, 2011  |   Pubmed ID: 21163924
• PARP Inhibitors in BRCA1/BRCA2 Germline Mutation Carriers with Ovarian and Breast Cancer
  F1000 Biology Reports. 2010  |   Pubmed ID: 20948822
• Poly (ADP-ribose) Polymerase As a Novel Therapeutic Target in Cancer
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2010  |   Pubmed ID: 20823142
• CD157 in Ovarian Carcinoma: How Does It Help Us?
  Journal of the National Cancer Institute. Aug, 2010  |   Pubmed ID: 20639477
• Nuclear Factor KappaB Transcription Factors Are Coexpressed and Convey a Poor Outcome in Ovarian Cancer
  Cancer. Jul, 2010  |   Pubmed ID: 20564628
• Activation of NF-kappaB Signaling by Inhibitor of NF-kappaB Kinase Beta Increases Aggressiveness of Ovarian Cancer
  Cancer Research. May, 2010  |   Pubmed ID: 20424119
• Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity As Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2010  |   Pubmed ID: 20068097
• The Sumoylation Pathway is Dysregulated in Multiple Myeloma and is Associated with Adverse Patient Outcome
  Blood. Apr, 2010  |   Pubmed ID: 19965618
• Uterine Papillary Serous Carcinoma: a New Paradigm for Treatment?
  Cancer. Aug, 2009  |   Pubmed ID: 19452535
• Combination Targeted Therapy with Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2008  |   Pubmed ID: 18669456
• Lack of Reliability of CA125 Response Criteria with Anti-VEGF Molecularly Targeted Therapy
  Cancer. Apr, 2008  |   Pubmed ID: 18300236
• BAG-4/SODD and Associated Antiapoptotic Proteins Are Linked to Aggressiveness of Epithelial Ovarian Cancer
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2007  |   Pubmed ID: 18006758
• Frequent Engagement of the Classical and Alternative NF-kappaB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
  Cancer Cell. Aug, 2007  |   Pubmed ID: 17692804
• Proteomics in Clinical Trials and Practice: Present Uses and Future Promise
  Molecular & Cellular Proteomics : MCP. Oct, 2006  |   Pubmed ID: 16737951
• Is There a Genomic Basis for Primary Chemoresistance in Ovarian Cancer?
  Gynecologic Oncology. Jul, 2003  |   Pubmed ID: 12821333